Linderman Stephen W, Gelberman Richard H, Thomopoulos Stavros, Shen Hua
Department of Orthopaedic Surgery, Washington University, St. Louis, MO, United States; Department of Biomedical Engineering, Washington University, St. Louis, MO, United States.
Department of Orthopaedic Surgery, Washington University, St. Louis, MO, United States.
Oper Tech Orthop. 2016 Sep;26(3):206-215. doi: 10.1053/j.oto.2016.06.011.
The two primary factors leading to poor clinical results after intrasynovial tendon repair are adhesion formation within the digital sheath and repair-site elongation and rupture. As the outcomes following modern tendon multi-strand repair and controlled rehabilitation techniques are often unsatisfactory, alternative approaches, such as the application of growth factors and mesenchymal stem cells (MSCs), have become increasingly attractive treatment options. Successful biological therapies require carefully controlled spatiotemporal delivery of cells, growth factors, and biocompatible scaffold matrices in order to simultaneously (1) promote matrix synthesis at the tendon repair site leading to increased biomechanical strength and stiffness and (2) suppress matrix synthesis along the tendon surface and synovial sheath preventing adhesion formation. This review summarizes recent cell and biologic-based experimental treatments for flexor tendon injury, with an emphasis on large animal translational studies.
导致滑膜内肌腱修复后临床效果不佳的两个主要因素是指腱鞘内粘连形成以及修复部位延长和断裂。由于现代肌腱多股修复和控制性康复技术的效果往往不尽人意,诸如应用生长因子和间充质干细胞(MSCs)等替代方法已成为越来越有吸引力的治疗选择。成功的生物疗法需要对细胞、生长因子和生物相容性支架基质进行精确控制的时空递送,以便同时(1)促进肌腱修复部位的基质合成,从而提高生物力学强度和刚度,以及(2)抑制沿肌腱表面和滑膜鞘的基质合成,防止粘连形成。本综述总结了近期基于细胞和生物学的屈肌腱损伤实验性治疗方法,重点是大型动物转化研究。